Hormonal and clinical effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome

Citation
A. Szilagyi et al., Hormonal and clinical effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome, GYNECOL END, 14(5), 2000, pp. 337-341
Citations number
18
Categorie Soggetti
Reproductive Medicine
Journal title
GYNECOLOGICAL ENDOCRINOLOGY
ISSN journal
09513590 → ACNP
Volume
14
Issue
5
Year of publication
2000
Pages
337 - 341
Database
ISI
SICI code
0951-3590(200010)14:5<337:HACEOC>2.0.ZU;2-G
Abstract
The aim of the study was to evaluate the hormonal (focusing on the urinary steroid profile) and clinical effects of chronic gonadotropin-releasing hor mone (GnRH) agonist treatment in patients with polycystic ovary syndrome (P COS) suffering from hirsutism. A long-acting GnRH agonist was administered for 6 months in eight PCOS patients. Hormonal effects were measured by dete rmining serum luteinizing hormone (LH),follicle stimulating hormone (FSH), prolactin, testosterone and estradiol concentrations, and by profiling urin ary steroids using capillary gas chromatography of 24-hour urine samples. T o evaluate 5 alpha -reductase enzyme activity, the ratios of androsterone t o etiocholanolone and 5 alpha -tetrahydrocortisol to tetrahydrocortisol wer e calculated in urine samples. The ratio of androgen to cortisol metabolite s was also determined before, and 3 and 6 months after therapy. LH and estradiol levels were suppressed significantly after the first injec tion and testosterone after the second injection of the GnRH agonist. Thus, serum testosterone was normalized. Ratios of urinary steroids reflecting 5 alpha -reductase enzyme activity (androsterone to etiocholanolone and 5 al pha -tetrahydrocortisol to tetrahydrocortisol) and the ratio of androgen to cortisol metabolites decreased significantly after 3 months of treatment. Degree of hirsutism, assessed by Ferriman-Gallwey score, diminished after 6 months, but not significantly. In conclusion, our data show that long-acting GnRH agonist treatment of PCO S patients is effective in reducing serum and urinary androgen levels, but it is not accompanied by an effective reduction in hirsutism during a 6-mon th treatment period. A longer or a combined treatment would be needed to ac hieve significant improvement in hirsutism. Gas chromatographic profiling o f urinary steroids and the use of specific ratios of the excreted metabolit es seems to be a sensitive tool both in the diagnosis of PCOS and in monito ring ovarian suppression.